Dallas Innovates - September 2024
DALLAS (September 2024) – Almaden Genomics has launched a new Data Management and Informatics Services business to support its bioinformatics and computational biology solutions. This expansion underscores Almaden’s commitment to advancing life sciences research by providing innovative, scalable solutions that streamline data analysis and management across multiple domains, including drug discovery, diagnostics, and biotech research.
“As we introduced our self-service, multi-omics analytics platform, making science accessible to all, we found that many companies still struggle with the upstream complexities of data ingestion, management and governance,” said David Gascoigne, CEO of Almaden Genomics. “Launching this new business aligns with our vision of transforming the bioinformatics landscape by making complex data management more accessible and actionable.”
With the increasing complexity of biological data and the need for robust computational tools, Almaden Genomics’ new service business is designed to address the critical challenges faced by researchers, pharmaceutical companies, and biotech organizations.
Key Offerings Include:
“By empowering researchers with the right data tools, we can accelerate the pace of discovery in drug development, biomarker research, and more,” said Gascoigne.
About Almaden Genomics
Almaden Genomics is a leader in bioinformatics and data management, providing cutting-edge computational solutions for the life sciences industry. With expertise in AI-driven research and cloud-based data handling, Almaden Genomics supports innovation in drug discovery, diagnostics, and biotech research. Almaden Genomics is a Catalyze Partners portfolio company. For more information, visit almaden.io.
Featured on: